Men who have advanced stages of prostate cancer that has spread to other areas of the body (metastasized) may be prescribed Zytiga™ (abiraterone acetate). It comes in the form of a tablet that is taken once daily in combination with prednisone.
Zytiga works by decreasing production of testosterone in the body. The prostate cancer cells are stimulated by testosterone, so lowering testosterone levels can help slow down the growth rate of the cancer cells. Because this drug works by targeting testosterone production in the adrenal gland and the prostate cancer cells, Zytiga may be an effective medication for prostate cancer that has been resistant to other medical or surgical treatment that only worked to decrease testosterone made by the testes.
Clinical studies on the effectiveness of Zytiga have shown that using this drug in combination with prednisone can extend life by up to four months.
(Click Zytiga for more information on the effectiveness of Zytiga, details on how the drug works, dosing guidelines, and possible side effects.)
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Zytiga Web site. Available at: http://www.zytiga.com/. Accessed June 16, 2011.
Food and Drug Administration (FDA) news release. FDA approves Zytiga for late-stage prostate cancer. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm253055.htm. Accessed June 16, 2011.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed June 17, 2011.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click